PT1879654E - Combinação farmacêutica que compreende um agente antifúngico e uma substância ativa selecionada especialmente entre eugenol e carvacrol - Google Patents

Combinação farmacêutica que compreende um agente antifúngico e uma substância ativa selecionada especialmente entre eugenol e carvacrol Download PDF

Info

Publication number
PT1879654E
PT1879654E PT06744740T PT06744740T PT1879654E PT 1879654 E PT1879654 E PT 1879654E PT 06744740 T PT06744740 T PT 06744740T PT 06744740 T PT06744740 T PT 06744740T PT 1879654 E PT1879654 E PT 1879654E
Authority
PT
Portugal
Prior art keywords
carvacrol
active substance
therapeutically active
fluconazole
alone
Prior art date
Application number
PT06744740T
Other languages
English (en)
Portuguese (pt)
Inventor
Adnane Remmal
Original Assignee
Advanced Scient Developements
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Scient Developements filed Critical Advanced Scient Developements
Publication of PT1879654E publication Critical patent/PT1879654E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT06744740T 2005-05-13 2006-05-15 Combinação farmacêutica que compreende um agente antifúngico e uma substância ativa selecionada especialmente entre eugenol e carvacrol PT1879654E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2005/001317 WO2006120496A1 (fr) 2005-05-13 2005-05-13 Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l’ eugenol, le thymol, le borneol, et le carvacrol

Publications (1)

Publication Number Publication Date
PT1879654E true PT1879654E (pt) 2012-08-29

Family

ID=35427301

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06744740T PT1879654E (pt) 2005-05-13 2006-05-15 Combinação farmacêutica que compreende um agente antifúngico e uma substância ativa selecionada especialmente entre eugenol e carvacrol

Country Status (13)

Country Link
US (1) US20080214568A1 (enExample)
EP (1) EP1879654B1 (enExample)
JP (1) JP5410747B2 (enExample)
CN (1) CN101189044B (enExample)
BR (1) BRPI0610132B8 (enExample)
CA (1) CA2607561C (enExample)
DK (1) DK1879654T3 (enExample)
EA (1) EA014068B1 (enExample)
ES (1) ES2390472T3 (enExample)
MA (1) MA29907B1 (enExample)
PT (1) PT1879654E (enExample)
TN (1) TNSN07425A1 (enExample)
WO (2) WO2006120496A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041585T2 (hu) 2004-09-28 2019-05-28 Avivagen Inc Kompozíciók és eljárások súlygyarapodás és táplálék konverzió elõsegítésére
PL2214656T3 (pl) * 2007-10-26 2019-06-28 Avivagen Inc. Kompozycje i sposoby wzmacniania odpowiedzi immunologicznej
CA2771204C (en) 2009-04-30 2017-09-19 Chemaphor Inc. Methods and compositions for improving the health of animals
WO2011036048A1 (en) 2009-09-24 2011-03-31 Unilever Nv Disinfecting agent comprising eugenol, terpineol and thymol
BR112013013085B1 (pt) 2010-12-07 2018-02-14 Unilever N.V. Composição de cuidados orais, enxaguante bucal, creme dental, dentífrico, método para desinfetar a cavidade oral e uso de uma composição
CN102550610B (zh) * 2010-12-07 2014-12-10 菲勒斯株式会社 含有从红松球果中提取的植物杀菌素的天然抗菌剂及包含它的水果病害防除原料
JP2014509845A (ja) * 2011-02-07 2014-04-24 フイルメニツヒ ソシエテ アノニム 抗真菌性のフレーバリング成分およびフレーバリング組成物
EA024551B1 (ru) 2011-11-03 2016-09-30 Юнилевер Н.В. Индивидуальная композиция для очищения
JP5925605B2 (ja) * 2012-06-04 2016-05-25 花王株式会社 リパーゼ活性阻害剤、抗真菌剤、及びフケ抑制剤
WO2016057563A1 (en) 2014-10-08 2016-04-14 Pacific Northwest Diabetes Research Institute Methods and compositions for increasing the potency of antifungal agents
CN104642326B (zh) * 2015-02-16 2016-02-10 河南科技学院 一种含戊苯吡菌胺和香芹酚的杀菌组合物及其用途
WO2017209588A2 (fr) 2016-06-02 2017-12-07 Advanced Scientific Developements Formulation pharmaceutique de cinéol et d'amoxicilline
EP3490552B1 (en) 2016-07-26 2022-11-23 University of Southern California Selective bromodomain inhibition of fungal bdf1
CN113116916B (zh) * 2021-05-25 2023-07-04 河北医科大学第二医院 一种治疗妇科疾病的药物组合物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294645A (en) * 1993-06-14 1994-03-15 Doyle E. Chastain Using menth-1-en-9-ol to kill bacteria, yeast, and fungi
CA2106032C (en) * 1993-09-13 1995-11-07 Gamini Weeratunga Methods for the manufacture of fluconazole and forms thereof, intermediates useful in the manufacture thereof, and combinations comprising fluconazole
WO1995019179A1 (en) * 1994-01-14 1995-07-20 Xoma Corporation Anti-fungal methods and materials
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6319507B1 (en) * 1997-05-02 2001-11-20 Kobo Products, Inc. Agar gel bead composition and method
US6414036B1 (en) * 1999-09-01 2002-07-02 Van Beek Global/Ninkov Llc Composition for treatment of infections of humans and animals
AU2002217316A1 (en) * 2001-01-03 2002-07-30 Medpharma Plc Use of terpenes for the treatment of digestive tract infections
JP2002284702A (ja) * 2001-01-19 2002-10-03 Teika Seiyaku Kk 外用抗真菌製剤
WO2002062316A1 (de) * 2001-02-08 2002-08-15 Vectron Therapeutics Ag Invasomen zur therapie von erkrankungen, ihre herstellung und verwendung
JP2002363070A (ja) * 2001-06-06 2002-12-18 Yuutoku Yakuhin Kogyo Kk 経皮吸収貼付剤
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
AU2002360517A1 (en) * 2001-12-07 2003-06-23 Ximed Group Plc Respiratory infection prevention and treatment with terpene-containing compositions
US20030225003A1 (en) * 2002-04-18 2003-12-04 Dusan Ninkov Antimicrobial therapeutic compositions for oral and topical use
US20040151771A1 (en) * 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
US20050014730A1 (en) * 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil

Also Published As

Publication number Publication date
DK1879654T3 (da) 2012-08-20
JP5410747B2 (ja) 2014-02-05
WO2006120565A3 (fr) 2007-08-23
EA200702482A1 (ru) 2008-04-28
JP2008540506A (ja) 2008-11-20
TNSN07425A1 (fr) 2009-03-17
ES2390472T3 (es) 2012-11-13
EP1879654B1 (fr) 2012-07-04
CA2607561A1 (fr) 2006-11-16
US20080214568A1 (en) 2008-09-04
BRPI0610132A2 (pt) 2012-09-25
CN101189044A (zh) 2008-05-28
CN101189044B (zh) 2011-12-07
WO2006120565A2 (fr) 2006-11-16
EP1879654A2 (fr) 2008-01-23
EA014068B1 (ru) 2010-08-30
WO2006120496A1 (fr) 2006-11-16
BRPI0610132B8 (pt) 2021-05-25
CA2607561C (fr) 2014-02-04
BRPI0610132B1 (pt) 2020-08-11
MA29907B1 (fr) 2008-11-03

Similar Documents

Publication Publication Date Title
AU2017283785A1 (en) Synergistic antifungal compositions and methods thereof
WO2017216722A2 (en) Synergistic antifungal compositions and methods thereof
ES2390472T3 (es) Combinación farmacéutica que comprende un agente antifúngico y un principio activo que es especialmente eugenol o carvacrol
JP2013535422A5 (enExample)
EP2707007B1 (en) Antifungal compositions for the treatment of nails
CN107249584A (zh) 用于抑制真菌感染的组合物和方法
BRPI0610125A2 (pt) composição farmacêutica, kit e utilização de uma composição
EP2814317B1 (en) Antifungal compositions for use in treatment of a skin disease
PT1879656E (pt) Composição farmacêutica compreendendo um agente antitumoral e um agente activo escolhido entre carveol, timol e carvacrol
WO2023246487A1 (zh) 一种抗真菌药物增效剂
CN107073124B (zh) 增效的抗微生物剂
JP7214714B2 (ja) 酸性ｐＨで活性の増強を示す抗真菌剤
JP2021521278A (ja) 抗感染症製剤
Orosz Antifungal drug therapy in avian species
US6660761B2 (en) Method of treatment for fungal infections with a synergistic formulation of antifungal agents
Mandal Evaluating the impact of antifungal drugs on human health and exploring alternative treatments.
PT2136816E (pt) Oleilfosfocolina
Sharma et al. A short review on liquisolid technology in anti-fungal drugs: https://doi. org/10.54037/WJPS. 2022.100116
CA2479381C (en) A use of treatment for fungal infections with a synergistic formulation of antifungal agent, menthol and menthyl acetate
JPH092970A (ja) 抗真菌剤
ES2732941T3 (es) Oleilfosfocolina para el tratamiento de la micosis
ES2844933T3 (es) Tulatromicina potenciada
WO2025149101A1 (es) Composición antifúngica y método de tratamiento
CN121398802A (zh) 药品及相关方法
Sekgele Modulation of Antifungal Drug Resistance and Combination Activity of Eugenol Tosylate Congeners With Antifungal Drugs in Candida Albicans